Biologics

Inside Mabion’s Transformation Gregor Kawaletz on Scaling, Strategy & Biologic CDMO Ambitions

Executing Mabion’s CDMO Vision: Insights from CEO Gregor Kawaletz

Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics

Gregor Kawaletz featured on Making It in Manufacturing podcast

evaluating a CDMO proposal and RFP process

Mabion’s Article about RFP process named one of the Top 10 Industry Insights of 2025 by Outsourced Pharma

Declaration of the objectives and scope of the European Biotech Act

Declaration of the objectives and scope of the European Biotech Act

Biologics CDMO Excellence Awards Europe 2025 Tech Transfer Team of the Year for Mabion Biologics CDMO

Mabion’s Tech Transfer Team wins Biologics CDMO Excellence Europe 2025

Mabion Awards €500,000 CDMO Services to WPD Pharmaceuticals for Breakthrough ADC Project

Mabion Awards €500,000 CDMO Services to WPD Pharmaceuticals for Breakthrough ADC Project

2025 CDMO Leadership Awards Europe highlights Mabion’s dedication to quality, expertise, and service, as judged directly by the biopharma partners. International CDMO for Biologics

Mabion is a Biologics CDMO Leadership Award Europe Finalist

NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy with Mabion manufacturing capacity.

Mabion Participates in Groundbreaking Clinical Trial of Self-Regulating Immunotherapy

Biologics CDMO is calling. Read more about the biopharma market outlook from Marty and Nigel.

Biologics CDMO Market – Mabion Approach to Establishing Cooperation